CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON) : study protocol for a phase IB/IIA randomised controlled trial

Coleman, R., Brown, J., Rathbone, E. et al. (9 more authors) (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON) : study protocol for a phase IB/IIA randomised controlled trial. Trials, 21 (1). 89.

Abstract

Metadata

Authors/Creators:
  • Coleman, R.
  • Brown, J.
  • Rathbone, E.
  • Flanagan, L.
  • Reid, A.
  • Kendall, J.
  • Howell, S.
  • Twelves, C.
  • Palmieri, C.
  • Anand, A.
  • MacPherson, I.
  • Brown, S.
Copyright, Publisher and Additional Information: © 2020 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: Radium-223; Capecitabine; Bone metastases; Bone turnover markers; Breast cancer
Dates:
  • Accepted: 9 August 2019
  • Published (online): 15 January 2020
  • Published: December 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 09 Mar 2020 16:04
Last Modified: 11 Mar 2020 07:39
Status: Published
Publisher: BioMed Central
Refereed: Yes
Identification Number: https://doi.org/10.1186/s13063-019-3643-6
Related URLs:

Share / Export

Statistics